ONC

SEC source: 0001682735-18-000003 · wf-form4_154212240992906.xml · nonDerivative · entry 7

Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.50 to $128.4999, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price.

SEC source: 0001682735-18-000003 · wf-form4_154212240992906.xml · nonDerivative · entry 6

Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.4616 to $127.4615, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price.

SEC source: 0001682735-18-000003 · wf-form4_154212240992906.xml · nonDerivative · entry 5

Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,873

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.45 to $126.4499, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price.

SEC source: 0001682735-18-000003 · wf-form4_154212240992906.xml · nonDerivative · entry 4

Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,822

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.18 to $125.1799, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price.

SEC source: 0001682735-18-000003 · wf-form4_154212240992906.xml · nonDerivative · entry 3

Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,245

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.34 to $123.3399, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price.

SEC source: 0001682735-18-000003 · wf-form4_154212240992906.xml · nonDerivative · entry 2

Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,711

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · price: The exercise price is represented in American Depositary Shares.

SEC source: 0001182489-18-000361 · edgar.xml · nonDerivative · entry 1

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $174.52 to $174.881, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001179110-18-011044 · edgar.xml · nonDerivative · entry 2

Glazer Donald W. · CIK 0001660940 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,384

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

SEC source: 0001179110-18-011044 · edgar.xml · nonDerivative · entry 1

Glazer Donald W. · CIK 0001660940 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,384

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

SEC source: 0001179110-18-010878 · edgar.xml · nonDerivative · entry 4

Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.30 to $170.87, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001179110-18-010878 · edgar.xml · nonDerivative · entry 3

Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 961

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $169.27 to $170.19, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001179110-18-010878 · edgar.xml · nonDerivative · entry 2

Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,361

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.25 to $169.24, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001179110-18-010878 · edgar.xml · nonDerivative · entry 1

Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,661

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.05 to $167.77, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001179110-18-010604 · edgar.xml · nonDerivative · entry 3

Wang Xiaodong · CIK 0001662982 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected to fulfill a tax payment obligation in connection with the vesting of a restricted share unit award previously granted to the Reporting Person.

SEC source: 0001179110-18-010604 · edgar.xml · nonDerivative · entry 2

Wang Xiaodong · CIK 0001662982 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 549

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected to fulfill a tax payment obligation in connection with the vesting of a restricted share unit award previously granted to the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.08 to $160.02, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001179110-18-010604 · edgar.xml · nonDerivative · entry 1

Wang Xiaodong · CIK 0001662982 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,249

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected to fulfill a tax payment obligation in connection with the vesting of a restricted share unit award previously granted to the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $157.00 to $157.74, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001638599-18-000886 · doc4_5577.xml · nonDerivative · entry 6

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 5,250,491

F7 · price: On August 2, 2018, 667 and Life Sciences purchased 582,200 and 5,231,900 Ordinary Shares of the Issuer, respectively in the Issuer's Hong Kong underwritten public offering at a price of HK$108 per Ordinary Share. The Ordinary Shares will trade under the trading symbol 6160 HK.

F3 · ownership.nature: Ordinary shares of the Issuer are convertible into ADS on a 13:1 basis.

F5 · ownership.nature: As a result of their ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the Issuer's Ordinary Shares or ADS, as applicable, reported in column 5 of Table I directly held by Baker Brothers Life Sciences, L.P. ("Life Sciences", together with 667, the "Funds"), a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

F6 · ownership.nature: 6,533,124 and 73,162,011 Ordinary Shares of the Issuer held by 667 and Life Sciences, respectively were converted into 502,548 and 5,627,847 ADS held by 667 and Life Sciences, respectively, without consideration and without a change in pecuniary interest.

F7 · ownership.nature: On August 2, 2018, 667 and Life Sciences purchased 582,200 and 5,231,900 Ordinary Shares of the Issuer, respectively in the Issuer's Hong Kong underwritten public offering at a price of HK$108 per Ordinary Share. The Ordinary Shares will trade under the trading symbol 6160 HK.

F8 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F9 · ownership.nature: Includes beneficial ownership of 9,290 restricted share units ("RSU's) convertible solely into Ordinary Shares of the Issuer each previously granted to Michael Goller and Ranjeev Krishana, full-time employees of the Adviser in their capacity as directors of the Issuer. Michael Goller and Ranjeev Krishana serve on the Board of the Issuer as representatives of the Funds.

F10 · ownership.nature: Pursuant to the policies of the Adviser, Michael Goller and Ranjeev Krishana do not have any right to any of the Issuer's securities issued as part of their service on the Board and the Funds are entitled to receive all the pecuniary interest in the securities issued. The Funds each own an indirect proportionate pecuniary interest in the RSU's and non-qualified share options convertible solely into Ordinary Shares of the Issuer ("Share Options") received as a result of their service on the Board. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interest in the general partners of the general partners of the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the RSU's and Share Options (i.e. no direct pecuniary interest).

SEC source: 0001638599-18-000886 · doc4_5577.xml · nonDerivative · entry 5

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 600,791

F7 · price: On August 2, 2018, 667 and Life Sciences purchased 582,200 and 5,231,900 Ordinary Shares of the Issuer, respectively in the Issuer's Hong Kong underwritten public offering at a price of HK$108 per Ordinary Share. The Ordinary Shares will trade under the trading symbol 6160 HK.

F3 · ownership.nature: Ordinary shares of the Issuer are convertible into ADS on a 13:1 basis.

F4 · ownership.nature: As a result of their ownership interest in Baker Biotech Capital (GP), LLC, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the Issuer's Ordinary Shares or ADS, as applicable, reported in column 5 of Table I directly held by 667, L.P. ("667"), a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F6 · ownership.nature: 6,533,124 and 73,162,011 Ordinary Shares of the Issuer held by 667 and Life Sciences, respectively were converted into 502,548 and 5,627,847 ADS held by 667 and Life Sciences, respectively, without consideration and without a change in pecuniary interest.

F7 · ownership.nature: On August 2, 2018, 667 and Life Sciences purchased 582,200 and 5,231,900 Ordinary Shares of the Issuer, respectively in the Issuer's Hong Kong underwritten public offering at a price of HK$108 per Ordinary Share. The Ordinary Shares will trade under the trading symbol 6160 HK.

F8 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F9 · ownership.nature: Includes beneficial ownership of 9,290 restricted share units ("RSU's) convertible solely into Ordinary Shares of the Issuer each previously granted to Michael Goller and Ranjeev Krishana, full-time employees of the Adviser in their capacity as directors of the Issuer. Michael Goller and Ranjeev Krishana serve on the Board of the Issuer as representatives of the Funds.

F10 · ownership.nature: Pursuant to the policies of the Adviser, Michael Goller and Ranjeev Krishana do not have any right to any of the Issuer's securities issued as part of their service on the Board and the Funds are entitled to receive all the pecuniary interest in the securities issued. The Funds each own an indirect proportionate pecuniary interest in the RSU's and non-qualified share options convertible solely into Ordinary Shares of the Issuer ("Share Options") received as a result of their service on the Board. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interest in the general partners of the general partners of the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the RSU's and Share Options (i.e. no direct pecuniary interest).

SEC source: 0001179110-18-009757 · edgar.xml · nonDerivative · entry 1

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.00 to $164.44, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001179110-18-009115 · edgar.xml · derivative · entry 6

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,310,088

Underlying: Ordinary Shares · 1,310,088 shares

Expires 2028-06-25

F6 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

F6 · shares: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

F7 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on June 26, 2019, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon a change in control or certain termination events.

F6 · derivative.underlying_shares: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

F6 · balance_after: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

SEC source: 0001179110-18-009115 · edgar.xml · nonDerivative · entry 1

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,453,322

F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 26, 2018, subject to continued service. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.

SEC source: 0001179110-18-009114 · edgar.xml · derivative · entry 2

Liang Howard · CIK 0001663427 · CFO & Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 364,208

Underlying: Ordinary Shares · 364,208 shares

Expires 2028-06-25

F2 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

F2 · shares: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

F3 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on June 26, 2019, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon a sale event.

F2 · derivative.underlying_shares: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

F2 · balance_after: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

SEC source: 0001179110-18-009114 · edgar.xml · nonDerivative · entry 1

Liang Howard · CIK 0001663427 · CFO & Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,338

F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 26, 2018, subject to continued service. Unvested securities are subject to accelerated vesting upon a sale event.

SEC source: 0001179110-18-009113 · edgar.xml · derivative · entry 2

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 310,180

Underlying: Ordinary Shares · 310,180 shares

Expires 2028-06-25

F2 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

F2 · shares: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

F3 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on June 26, 2019, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control.

F2 · derivative.underlying_shares: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

F2 · balance_after: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

SEC source: 0001179110-18-009113 · edgar.xml · nonDerivative · entry 1

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 309,464

F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 26, 2018, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.

SEC source: 0001179110-18-009112 · edgar.xml · derivative · entry 2

Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 310,180

Underlying: Ordinary Shares · 310,180 shares

Expires 2028-06-25

F2 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

F2 · shares: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

F3 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on June 26, 2019, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control.

F2 · derivative.underlying_shares: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

F2 · balance_after: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

SEC source: 0001179110-18-009112 · edgar.xml · nonDerivative · entry 1

Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 269,566

F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 26, 2018, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.

SEC source: 0001179110-18-009111 · edgar.xml · derivative · entry 5

Wang Xiaodong · CIK 0001662982 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 655,044

Underlying: Ordinary Shares · 655,044 shares

Expires 2028-06-25

F5 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

F5 · shares: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

F6 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on June 26, 2019, and the remaining in 36 successive equal monthly installments, subject to continued service.

F5 · derivative.underlying_shares: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

F5 · balance_after: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

SEC source: 0001179110-18-009111 · edgar.xml · nonDerivative · entry 2

Wang Xiaodong · CIK 0001662982 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,973,444

F2 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 26, 2018, subject to continued service.

SEC source: 0001179110-18-009111 · edgar.xml · nonDerivative · entry 1

Wang Xiaodong · CIK 0001662982 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,879,311

F1 · balance_after: This a bona fide gift by the Reporting Person to Wang Investment LLC, which is owned by the Reporting Person and his wife.

SEC source: 0001638599-18-000624 · doc4_5454.xml · derivative · entry 7

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 34,884

Underlying: Ordinary Shares · 34,884 shares

Expires 2028-06-05

F3 · derivative.exercise_price: Ordinary shares of the Issuer are convertible into American Depository Shares ("ADS") on a 13:1 basis.

F3 · shares: Ordinary shares of the Issuer are convertible into American Depository Shares ("ADS") on a 13:1 basis.

F8 · shares: 17,442 non-qualified share options ("Share Options") convertible solely into Ordinary Shares of the Issuer each were granted to Michael Goller and Ranjeev Krishana, full-time employees of the Adviser in their capacity as directors of the Issuer. The Share Options with a strike price of $16.15 vest upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting provided, however, that all vesting shall cease if Michael Goller or Ranjeev Krishana resigns from the Board of Directors (the "Board") or otherwise ceases to serve as a director, unless the Board determines otherwise. The Share Options expire on June 5, 2028. Michael Goller and Ranjeev Krishana serve on the Board of the Issuer as representatives of the Funds. Unvested Share Options are subject to accelerated vesting upon a change in control or certain termination events.

F8 · derivative.exercise_date: 17,442 non-qualified share options ("Share Options") convertible solely into Ordinary Shares of the Issuer each were granted to Michael Goller and Ranjeev Krishana, full-time employees of the Adviser in their capacity as directors of the Issuer. The Share Options with a strike price of $16.15 vest upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting provided, however, that all vesting shall cease if Michael Goller or Ranjeev Krishana resigns from the Board of Directors (the "Board") or otherwise ceases to serve as a director, unless the Board determines otherwise. The Share Options expire on June 5, 2028. Michael Goller and Ranjeev Krishana serve on the Board of the Issuer as representatives of the Funds. Unvested Share Options are subject to accelerated vesting upon a change in control or certain termination events.

F3 · derivative.underlying_shares: Ordinary shares of the Issuer are convertible into American Depository Shares ("ADS") on a 13:1 basis.

F3 · ownership.nature: Ordinary shares of the Issuer are convertible into American Depository Shares ("ADS") on a 13:1 basis.

F8 · ownership.nature: 17,442 non-qualified share options ("Share Options") convertible solely into Ordinary Shares of the Issuer each were granted to Michael Goller and Ranjeev Krishana, full-time employees of the Adviser in their capacity as directors of the Issuer. The Share Options with a strike price of $16.15 vest upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting provided, however, that all vesting shall cease if Michael Goller or Ranjeev Krishana resigns from the Board of Directors (the "Board") or otherwise ceases to serve as a director, unless the Board determines otherwise. The Share Options expire on June 5, 2028. Michael Goller and Ranjeev Krishana serve on the Board of the Issuer as representatives of the Funds. Unvested Share Options are subject to accelerated vesting upon a change in control or certain termination events.

F9 · ownership.nature: Pursuant to the policies of the Adviser, Michael Goller and Ranjeev Krishana do not have any right to any of the Issuer's securities issued as part of their service on the Board and the Funds are entitled to receive all the pecuniary interest in the securities issued. The Funds each own an indirect proportionate pecuniary interest in the RSU's and Share Options. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interest in the general partners of the general partners of the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the RSU's and Share Options (i.e. no direct pecuniary interest).

F10 · ownership.nature: The disclosure of the grant of RSU's and Share Options reported on this form is a grant of 9,290 RSU's and 17,442 Share Options to each director referenced above. The 18,580 RSU's and 34,884 Share Options are reported for each of the Funds as each has an indirect pecuniary interest.

F11 · ownership.nature: As a result of their ownership interest in Baker Biotech Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 34,884 Share Options to purchase Ordinary Shares of the Issuer beneficially owned by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F12 · ownership.nature: As a result of their ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 34,884 Share Options to purchase Ordinary Shares of the Issuer beneficially owned by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0001638599-18-000624 · doc4_5454.xml · nonDerivative · entry 6

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 73,180,602

F3 · ownership.nature: Ordinary shares of the Issuer are convertible into American Depository Shares ("ADS") on a 13:1 basis.

F5 · ownership.nature: As a result of their ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the Issuer's Ordinary Shares or ADS, as applicable, reported in column 5 of Table I directly held by Baker Brothers Life Sciences, L.P. ("Life Sciences", together with 667, the "Funds"), a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

F6 · ownership.nature: 9,290 restricted share units ("RSU's") convertible solely into Ordinary Shares of the Issuer were each granted on June 6, 2018 to Michael Goller and Ranjeev Krishana, full-time employees of the Adviser (as defined below) in their capacity as directors of the Issuer. The RSU's vest upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting, subject to continued service. Unvested RSU's are subject to accelerated vesting upon a change in control or certain termination events.

F7 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F9 · ownership.nature: Pursuant to the policies of the Adviser, Michael Goller and Ranjeev Krishana do not have any right to any of the Issuer's securities issued as part of their service on the Board and the Funds are entitled to receive all the pecuniary interest in the securities issued. The Funds each own an indirect proportionate pecuniary interest in the RSU's and Share Options. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interest in the general partners of the general partners of the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the RSU's and Share Options (i.e. no direct pecuniary interest).

F10 · ownership.nature: The disclosure of the grant of RSU's and Share Options reported on this form is a grant of 9,290 RSU's and 17,442 Share Options to each director referenced above. The 18,580 RSU's and 34,884 Share Options are reported for each of the Funds as each has an indirect pecuniary interest.

SEC source: 0001638599-18-000624 · doc4_5454.xml · nonDerivative · entry 5

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 6,551,715

F3 · ownership.nature: Ordinary shares of the Issuer are convertible into American Depository Shares ("ADS") on a 13:1 basis.

F4 · ownership.nature: As a result of their ownership interest in Baker Biotech Capital (GP), LLC, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the Issuer's Ordinary Shares or ADS, as applicable, reported in column 5 of Table I directly held by 667, L.P. ("667"), a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F6 · ownership.nature: 9,290 restricted share units ("RSU's") convertible solely into Ordinary Shares of the Issuer were each granted on June 6, 2018 to Michael Goller and Ranjeev Krishana, full-time employees of the Adviser (as defined below) in their capacity as directors of the Issuer. The RSU's vest upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting, subject to continued service. Unvested RSU's are subject to accelerated vesting upon a change in control or certain termination events.

F7 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F9 · ownership.nature: Pursuant to the policies of the Adviser, Michael Goller and Ranjeev Krishana do not have any right to any of the Issuer's securities issued as part of their service on the Board and the Funds are entitled to receive all the pecuniary interest in the securities issued. The Funds each own an indirect proportionate pecuniary interest in the RSU's and Share Options. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interest in the general partners of the general partners of the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the RSU's and Share Options (i.e. no direct pecuniary interest).

F10 · ownership.nature: The disclosure of the grant of RSU's and Share Options reported on this form is a grant of 9,290 RSU's and 17,442 Share Options to each director referenced above. The 18,580 RSU's and 34,884 Share Options are reported for each of the Funds as each has an indirect pecuniary interest.

SEC source: 0000902664-18-002540 · p18-1312form4.xml · derivative · entry 2

Yi Qingqing · CIK 0001662556 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,442

Underlying: Ordinary Shares · 17,442 shares

Expires 2028-06-05

F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.

F2 · derivative.underlying_shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

F2 · balance_after: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

SEC source: 0000902664-18-002540 · p18-1312form4.xml · nonDerivative · entry 1

Yi Qingqing · CIK 0001662556 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,290

F1 · security: Represents securities underlying restricted share units ("RSUs"). All securities will vest upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.

SEC source: 0001104659-18-039249 · a4.xml · derivative · entry 5

Glazer Donald W. · CIK 0001660940 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,442

Underlying: Ordinary Shares · 17,442 shares

Expires 2028-06-05

F4 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

F4 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

F5 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.

F4 · derivative.underlying_shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

F4 · balance_after: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

SEC source: 0001104659-18-039249 · a4.xml · nonDerivative · entry 3

Glazer Donald W. · CIK 0001660940 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,336,932

F3 · security: Represents securities underlying restricted share units ("RSUs"). All securities will vest upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.

SEC source: 0001104659-18-039248 · a4.xml · derivative · entry 2

Chen Timothy Yung-Cheng · CIK 0001374068 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,442

Underlying: Ordinary Shares · 17,442 shares

Expires 2028-06-05

F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.

F2 · derivative.underlying_shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

F2 · balance_after: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

SEC source: 0001104659-18-039248 · a4.xml · nonDerivative · entry 1

Chen Timothy Yung-Cheng · CIK 0001374068 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,290

F1 · security: Represents securities underlying restricted share units ("RSUs"). All securities will vest upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.

SEC source: 0001104659-18-039246 · a4.xml · derivative · entry 3

Malley Thomas · CIK 0001403322 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,442

Underlying: Ordinary Shares · 17,442 shares

Expires 2028-06-05

F3 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our ADSs on the date of grant, as each ADS represents 13 ordinary shares.

F3 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our ADSs on the date of grant, as each ADS represents 13 ordinary shares.

F4 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.

F3 · derivative.underlying_shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our ADSs on the date of grant, as each ADS represents 13 ordinary shares.

F3 · balance_after: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our ADSs on the date of grant, as each ADS represents 13 ordinary shares.

SEC source: 0001104659-18-039246 · a4.xml · nonDerivative · entry 1

Malley Thomas · CIK 0001403322 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,290

F1 · security: Represents securities underlying restricted share units ("RSUs"). All securities will vest upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.

SEC source: 0001179110-18-006092 · edgar.xml · derivative · entry 6

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 996,810

Underlying: Ordinary Shares · 996,810 shares

Expires 2028-04-29

F6 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

F6 · shares: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

F7 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on April 30, 2019, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon a change in control or certain termination events.

F6 · derivative.underlying_shares: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

F6 · balance_after: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

SEC source: 0001179110-18-006092 · edgar.xml · nonDerivative · entry 1

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,265,056

F1 · security: Represents securities underlying restricted share units ("RSUs"). 1/4th of the securities will vest on each anniversary of April 30, 2018, subject to continued service. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.

SEC source: 0001104659-18-029973 · a4.xml · derivative · entry 4

Wu Xiaobin · CIK 0001739452 · President & GM China

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 766,599

Underlying: Ordinary Shares · 766,599 shares

Expires 2028-04-29

F3 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our ADSs on the date of grant, as each ADS represents 13 ordinary shares.

F3 · shares: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our ADSs on the date of grant, as each ADS represents 13 ordinary shares.

F4 · derivative.exercise_date: These securities vest over a five-year period as follows: 20% on April 30, 2019, and the remaining in 48 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon a change in control or certain termination events.

F3 · derivative.underlying_shares: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our ADSs on the date of grant, as each ADS represents 13 ordinary shares.

F3 · balance_after: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our ADSs on the date of grant, as each ADS represents 13 ordinary shares.

SEC source: 0001104659-18-029973 · a4.xml · nonDerivative · entry 1

Wu Xiaobin · CIK 0001739452 · President & GM China

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,149,899

F1 · security: Represents securities underlying restricted share units ("RSUs"). 1/5th of the securities will vest on each anniversary of April 30, 2018, subject to continued service. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.

SEC source: 0001179110-18-005403 · edgar.xml · derivative · entry 1

su Jingshyh S · CIK 0001315720 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,290

Underlying: Ordinary Shares · 63,290 shares

Expires 2028-04-01

F1 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share ("ADS") represents 13 Ordinary Shares.

F1 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share ("ADS") represents 13 Ordinary Shares.

F2 · derivative.exercise_date: The option shall become exercisable in equal installments on the first, second and third anniversary of the grant date and shall become exercisable in full on the date of the third annual meeting of shareholders following the grant date. All vesting shall cease if the reporting person resigns from the board or otherwise ceases to serve as a director, unless the board determines that the circumstances warrant the continuation of vesting.

F1 · derivative.underlying_shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share ("ADS") represents 13 Ordinary Shares.

F1 · balance_after: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share ("ADS") represents 13 Ordinary Shares.

SEC source: 0001179110-18-004691 · edgar.xml · derivative · entry 15

Liang Howard · CIK 0001663427 · CFO & Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,445,000

Underlying: Ordinary Shares · 313,664 shares

Expires 2025-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F14 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.

F15 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on July 15, 2016, and the remaining in 36 successive equal monthly installments, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon a sale event or certain termination events.

SEC source: 0001179110-18-004691 · edgar.xml · nonDerivative · entry 13

Liang Howard · CIK 0001663427 · CFO & Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share ("ADS") represents 13 Ordinary Shares.

F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.16 to $165.03, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of ADSs sold at each separate price.

SEC source: 0001179110-18-004691 · edgar.xml · nonDerivative · entry 12

Liang Howard · CIK 0001663427 · CFO & Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 900

F1 · security: Each American Depositary Share ("ADS") represents 13 Ordinary Shares.

F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.16 to $164.15, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of ADSs sold at each separate price.

SEC source: 0001179110-18-004691 · edgar.xml · nonDerivative · entry 11

Liang Howard · CIK 0001663427 · CFO & Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,536

F1 · security: Each American Depositary Share ("ADS") represents 13 Ordinary Shares.

F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $162.15 to $163.13, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of ADSs sold at each separate price.